This document serves as a formal correction (erratum) to the previously published 12-month outcomes of the PSoHO study. While the core findings remain robust, this update provides essential clarifications regarding study design, outcome definitions, and statistical transparency to ensure the data is accurately interpreted by the clinical community.
Clarifying Study Design: A Prospective Approach
A significant update in this correction is the formal classification of the PSoHO study as prospective. In clinical research, a prospective observational study is planned before data collection begins, which generally offers higher evidentiary value than retrospective chart reviews. This distinction is vital for researchers and meta-analysts evaluating the strength of the real-world evidence provided by PSoHO.
Standardizing Outcome Definitions
To ensure reproducibility and clear comparison between different biologic treatments (such as IL-17 and IL-23 inhibitors), the authors have refined the definitions for "effectiveness" and "durability." These metrics serve as the benchmarks for success in the study.
As shown in the updated definitions, Effectiveness is primarily measured by:
- Primary Outcome: Achieving at least a 90% improvement in the Psoriasis Area and Severity Index (PASI90) or a static Physician’s Global Assessment (sPGA) score of 0 or 1.
- Quality of Life: Measured by the Dermatology Life Quality Index (DLQI), targeting a score of 0 or 1, indicating the disease no longer impacts the patient's life.
Beyond initial success, the study emphasizes Durability, which requires patients to maintain their response over time.
To meet the "Durability of Effectiveness" outcome, a patient must meet the primary criteria at week 12 and subsequently maintain specific improvement thresholds (like PASI75 or a 2-point sPGA improvement) through the 12-month mark.
Refining "Super Responder" Terminology
The correction also addresses the terminology used for "super responders"—patients who exhibit an exceptional response to biologic therapy. The authors removed the word "weight" in this context and updated citations to reflect the latest literature (e.g., Mastorino et al., 2022; Ruiz-Villaverde et al., 2022). This ensures that the discussion surrounding high-performing patients is grounded in current clinical understanding.
Conclusion and Significance
The primary "result" of this correction is the provision of a previously missing statistical appendix and the finalized definitions of study endpoints. By standardizing these metrics and clarifying the prospective nature of the trial, the authors enhance the transparency and utility of the PSoHO dataset. This real-world evidence remains a critical tool for understanding how biologics perform in everyday clinical practice across diverse patient populations.
Summary updated